Second-line immunotherapy in patients with metastatic melanoma
- PMID: 33989555
- DOI: 10.1016/S1470-2045(21)00190-X
Second-line immunotherapy in patients with metastatic melanoma
Conflict of interest statement
DEG is part of the advisory board for Bayer HealthCare Pharmaceuticals, Amgen, and QBiotics. AW declares no competing interests.
Comment on
-
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.Lancet Oncol. 2021 Jun;22(6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11. Lancet Oncol. 2021. PMID: 33989557
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical